Merck KGaA's Erbitux fails in colon cancer study
FRANKFURT (Reuters) - Germany's Merck KGaA said on Wednesday that Erbitux, one of its most important drugs, failed to help colon cancer patients after surgery in a late stage trial.
A scheduled interim analysis of the so-called Petacc-8 study, which tested Erbitux in combination with standard chemotherapy as a treatment of colon cancer that has started spreading, showed no improvement in disease-free survival compared with using chemotherapy only.
Merck's Erbitux competes with Amgen Vectibix in the market for certain colorectal cancer treatments and is also approved for treating head and neck cancer.
(Reporting by Ludwig Burger)
- Tweet this
- Share this
- Digg this
- Children's corpses reveal desperate attempts to escape Korean ferry |
- Russia says it will respond if Ukraine interests attacked |
- Australia, Malaysia vow to keep searching to solve plane mystery
- Search for MH370 reveals a military vulnerability for China
- UK says scrambles jets to see off Russian planes near Scotland